Latest News

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.

Gilead and AbbVie HCV meds face off in hard-to-treat

Gilead and AbbVie HCV meds face off in hard-to-treat

New data from the International Liver Congress in London this past weekend showed strong efficacy for Gilead's Sovaldi and AbbVie's combo regimen when paired with ribavirin.

GSK accused of wrongdoing in Poland, Wellbutrin generic revoked

Poland joins the list of countries in which GlaxoSmithKline is accused of misconduct. Meanwhile, bioequivalence issues have prompted the FDA to revoke its approval of GSK's Wellbutrin generic.

UK court OKs Herceptin biosimilar

A London court knocked down two Roche/Genentech patents, making a clearer path for biosimilars of the breast cancer drug. The primary patent lapses in July.

Sebelius leaves HHS

Politico calls her departure an "everybody wins" situation.

Email Newsletters